Peer-Reviewed Journal Details
Mandatory Fields
Daly, LE;Ni Bhuachalla, EB;Power, DG;Cushen, SJ;James, K;Ryan, AM
2018
April
Journal of Cachexia, Sarcopenia and Muscle
Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer
Validated
Optional Fields
CELL LUNG-CANCER BODY-MASS INDEX NEOADJUVANT CHEMOTHERAPY PANCREATIC-CANCER ESOPHAGOGASTRIC CANCER CLINICAL-IMPLICATIONS MULTIMODAL THERAPY COLORECTAL-CANCER SOLID TUMORS DOUBLE-BLIND
9
315
325
BackgroundMalnutrition, weight loss, and muscle wasting are common in patients with foregut cancers (oesophagus, stomach, pancreas, liver, and bile ducts) and are associated with adverse clinical outcomes. However, little is known about the changes in body composition that occur in these patients during chemotherapy and its impacts clinical outcomes. Patients and methodsA prospective study of adult foregut cancer patients undergoing chemotherapy between 2012 and 2016 was conducted. Computed tomography images were evaluated for cross-sectional skeletal muscle area (SMA) and adipose tissue area (ATA) at two time points [interval 118days (IQR 92-58days)]. Longitudinal changes in SMA and ATA were examined using paired t-tests. Sarcopenia and low muscle attenuation (MA) were defined using published cut-points. Cox proportional hazards models were used to estimate mortality hazard ratios for key predictors. ResultsA total of 225 foregut cancer patients were included (67% male, median age 66years). At baseline, 40% were sarcopenic, 49% had low MA, and 62% had cancer cachexia. Longitudinal analysis (n=163) revealed significant reductions in SMA [-6.1cm(2) (3.9%)/100days, P<0.001]. Patients treated with neoadjuvant chemotherapy experienced greater losses in SMA and skeletal muscle mass compared with patients receiving palliative chemotherapy [-6.6cm(2) (95%, confidence interval, CI: -10.2 to -3.1), P<0.001 and -1.2kg (95% CI: -1.8 to -0.5), P<0.001, respectively]. Neither sarcopenia nor low MA at baseline was associated with reduced survival. A loss of SMA >6.0%/100days (highest fourth) independently predicted overall survival in patients receiving palliative chemotherapy [hazard ratio: 2.66, (95% CI: 1.42 to 4.97), P=0.002]. ConclusionsPatients with foregut cancers, particularly those treated with neoadjuvant chemotherapy, experience significant losses of muscle during chemotherapy. A high level of SMA loss is prognostic of reduced survival in patients treated with palliative chemotherapy. Multimodal interventions to stabilize or increase muscle mass and influence outcome warrant further investigation.
HOBOKEN
2190-6009
10.1002/jcsm.12267
Grant Details